Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.62 SEK | +2.31% | -3.12% | -49.59% |
Apr. 16 | Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed | CI |
Mar. 08 | Transcript : Nanexa AB - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-49.59% | 7.5M | |
-8.89% | 187M |
- Stock Market
- Equities
- NANEXA Stock
- News Nanexa AB
- Nanexa, VitriVax Settle Patent Infringement Case Over Drug Delivery System